Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics-Reference-Cited by-同舟云学术

Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics

Published:2021-06-15 Issue:7 Volume:21 Page:945-962
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Saini Kamal S¹^ORCID,Punie Kevin²³,Twelves Chris⁴,Bortini Stefanella¹,de Azambuja Evandro⁵⁶^ORCID,Anderson Steven¹,Criscitiello Carmen⁷⁸,Awada Ahmad⁵^ORCID,Loi Sherene⁹

Affiliation:

1. Clinical Development Services, Covance Inc, Princeton, NJ, USA

2. Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium

3. Laboratory of Experimental Oncology, Department of Oncology, KU Leuven, Leuven, Belgium

4. Leeds Institute of Medical Research, University of Leeds and Leeds Teaching Hospitals Trust, Leeds, UK

5. Medical Support Team (Academic Promoting Team), Institut Jules Bordet, Brussels, Belgium

6. Faculté de Médecine, Université Libre De Bruxelles (U.L.B.), Brussels, Belgium

7. Division of Early Drug Development for Innovative Therapy, European Institute of Oncology, IRCCS, Milan, Italy

8. Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy

9. Division of Research and Clinical Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia

Funder

funded

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2021.1936494

Reference200 articles.

1. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

2. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

3. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study

4. Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan

5. Last but not least: antibody–drug conjugates in hormone receptor-positive metastatic breast cancer

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synergizing Immunotherapy and Antibody–Drug Conjugates: New Horizons in Breast Cancer Therapy;Pharmaceutics;2024-08-29

2. Advancements in triple-negative breast cancer sub-typing, diagnosis and treatment with assistance of artificial intelligence : a focused review;Journal of Cancer Research and Clinical Oncology;2024-08-06

3. Beyond Anti-PD-1/PD-L1: Improving Immune Checkpoint Inhibitor Responses in Triple-Negative Breast Cancer;Cancers;2024-06-11

4. When will the immune-stimulating antibody conjugates (ISACs) be transferred from bench to bedside?;Pharmacological Research;2024-05

5. Characterization of MYBL1 Gene in Triple-Negative Breast Cancers and the Genes’ Relationship to Alterations Identified at the Chromosome 8q Loci;International Journal of Molecular Sciences;2024-02-22